ÂÜÀòÂÒÂ×

Geoff Porges, MBBS., is chief financial officer. He joined ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù in 2022 to lead the company’s financial operations, investor relations and corporate affairs activities, and business development and strategic planning for the company’s proprietary pharmaceuticals and biopharmaceutical collaborations. Geoff joined ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù from SVB Securities, where he was most recently vice chairman. From 2015 until 2022, he was senior managing director, director of therapeutics research and senior research analyst at SVB Securities and at Leerink prior to its acquisition by SVB Securities. In that capacity, he led the Leerink/SVB therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was the biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, Geoff held executive positions at BTG plc and Merck, including leading the commercialization of Merck’s human vaccines. Geoff earned his medical degree from the University of Sydney and trained in pediatric and internal medicine in Australia. He is also a graduate of Harvard Business School where he was a Baker Scholar.